Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Type I Clear all

Conditions: Type 1 Diabetes
Interventions: Pramlintide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 70
States / cities: Little Rock, Arkansas • Concord, California • Encino, California + 60 more

Conditions: Type1diabetes
Interventions: MyT1DHero, Other T1D Mobile App; Device
Lead sponsor: Michigan State University; Other
Eligibility: 10 Years to 15 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP); Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Burlingame, California • Tallahassee, Florida

Conditions: Diabetes Mellitus, Diabetes Type 1
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: Blood Glucose Awareness Training for Parents; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 11 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus
Interventions: FreeStyle Libre 3 continuous glucose monitoring sensor, Nutritional drink; Device · Other
Lead sponsor: Samita Garg; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type1diabetes, Type1 Diabetes Mellitus
Interventions: VSL#3; Dietary Supplement
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes Mellitus
Interventions: Decision Support System, Usual Care; Device · Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Acetylated and Butyrylated High Amylose Maize Starch; Drug
Lead sponsor: Indiana University; Other
Eligibility: 11 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitus
Interventions: Spotlight AQ Survey platform; Other
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 16 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Type1 Diabetes
Interventions: Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP); Device
Lead sponsor: Yale University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions: CGM; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Type1 Diabetes
Interventions: HCL, verapamil 120mg tablet, non-HCL, placebo; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Type 1 Diabetes, Eating Disorder
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 12 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: Dasiglucagon, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chula Vista, California • Escondido, California • Renton, Washington

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 68 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: FlexTouch®, FlexPen®; Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 65
States / cities: Burlingame, California • Concord, California • Encino, California + 59 more

Conditions: Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Cytal Wound Matrix 1-Layer, Standard of Care (SOC); Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland

Conditions: Type I Diabetes
Interventions: NNC0361-0041, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Diabetes Mellitus, Type 1
Interventions: TOL-3021, TOL-3021 Placebo; Biological · Other
Lead sponsor: Tolerion, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • San Mateo, California + 20 more

Conditions: Type 1 Diabetes
Interventions: Sleep-Opt, Healthy Living; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type1diabetes
Interventions: BKR-017; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

MyT1DHero: an mHealth Intervention for Type 1 Diabetes

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

Green Digital Diabetes Waste Project

ACZ885 in Type 1 Diabetes Mellitus

Blood Glucose Awareness Training for Parents

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID)

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Islet Cell Transplant for Type 1 Diabetes

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes

Butyrate Adjuvant Therapy for Type 1 Diabetes